Erschienen in:
15.12.2017 | Neurology and Preclinical Neurological Studies - Original Article
Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson’s disease
verfasst von:
Adjia Hamadjida, Stephen G. Nuara, Jim C. Gourdon, Philippe Huot
Erschienen in:
Journal of Neural Transmission
|
Ausgabe 9/2018
Einloggen, um Zugang zu erhalten
Abstract
Trazodone is a clinically available anti-depressant that exhibits affinity for serotonin 1A and 2A receptors, as well as for alpha-adrenoceptors, suggesting that it may be useful to treat l-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesia and psychosis that are encountered in advanced Parkinson’s disease (PD). Here, we investigated the anti-dyskinetic and anti-psychotic effects of trazodone in the parkinsonian non-human primate. 6 common marmosets were rendered parkinsonian by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Following repeated administration of l-DOPA to induce stable dyskinesia and psychosis-like behaviours (PLBs), trazodone (0.1, 1 and 10 mg/kg) or vehicle was administered in combination with l-DOPA and its effects on dyskinesia, PLBs and parkinsonism were determined. The addition of trazodone 10 mg/kg to l-DOPA reduced peak dose dyskinesia by ≈ 39% (P < 0.01) and peak dose PLBs by ≈ 17% (P < 0.01). However, parkinsonian disability was significantly worsened by trazodone 10 mg/kg (P < 0.05) and duration of anti-parkinsonian action was diminished by ≈ 21% (P < 0.05). Our results suggest that trazodone may be effective in alleviating l-DOPA-induced dyskinesia and psychosis in PD, but its deleterious effect on motor function is a concern and may limit its tolerability and usefulness in clinical settings.